The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Expands manufacturing push & locks in major growth deals
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
The standout story remains Wegovy, particularly its new oral formulation
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
